◎ Sugi Atlas

Atlas / Gene / CA6

CA6

gene
On this page

Summary

CA6 (carbonic anhydrase 6, HGNC:1380) is a protein-coding gene on chromosome 1p36.23, encoding Carbonic anhydrase 6 (P23280). Reversible hydration of carbon dioxide.

The protein encoded by this gene is one of several isozymes of carbonic anhydrase. This protein is found only in salivary glands and saliva and protein may play a role in the reversible hydratation of carbon dioxide though its function in saliva is unknown.

Source: NCBI Gene 765 — RefSeq curated summary.

At a glance

  • GWAS associations: 3
  • Clinical variants (ClinVar): 66 total — 2 pathogenic, 1 likely-pathogenic
  • Druggable target: yes — 47 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_001215

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:1380
Approved symbolCA6
Namecarbonic anhydrase 6
Location1p36.23
Locus typegene with protein product
StatusApproved
Ensembl geneENSG00000131686
Ensembl biotypeprotein_coding
OMIM114780
Entrez765

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000377436, ENST00000377442, ENST00000377443, ENST00000476083, ENST00000480186, ENST00000549778

RefSeq mRNA: 4 — MANE Select: NM_001215 NM_001215, NM_001270500, NM_001270501, NM_001270502

CCDS: CCDS30578, CCDS57970, CCDS57971

Canonical transcript exons

ENST00000377443 — 8 exons

ExonStartEnd
ENSE0000073988989571378957285
ENSE0000184279789458688945965
ENSE0000194896689746228975092
ENSE0000284671889492638949442
ENSE0000353123589625878962656
ENSE0000364229189589108959002
ENSE0000365033489708678970981
ENSE0000369329589676598967816

Expression profiles

Bgee: expression breadth ubiquitous, 108 present calls, max score 100.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 49.3086 / max 48869.9940, expressed in 37 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
47549.308637

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
parotid glandUBERON:0001831100.00gold quality
upper arm skinUBERON:000426395.71gold quality
upper leg skinUBERON:000426294.07gold quality
skin of legUBERON:000151187.15gold quality
zone of skinUBERON:000001485.11gold quality
skin of hipUBERON:000155482.94gold quality
skin of abdomenUBERON:000141681.51gold quality
diaphragmUBERON:000110381.23gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099176.87gold quality
mammalian vulvaUBERON:000099776.53gold quality
cauda epididymisUBERON:000436069.39gold quality
tongue squamous epitheliumUBERON:000691969.37gold quality
hair follicleUBERON:000207367.35gold quality
tongueUBERON:000172366.81gold quality
superior surface of tongueUBERON:000737165.41gold quality
buccal mucosa cellCL:000233664.65gold quality
tonsilUBERON:000237264.58gold quality
vastus lateralisUBERON:000137963.78gold quality
granulocyteCL:000009463.25gold quality
quadriceps femorisUBERON:000137762.80gold quality
nippleUBERON:000203062.35gold quality
epithelium of nasopharynxUBERON:000195161.50gold quality
olfactory bulbUBERON:000226461.26gold quality
type B pancreatic cellCL:000016961.12gold quality
bloodUBERON:000017860.98gold quality
body of tongueUBERON:001187659.99gold quality
lymph nodeUBERON:000002959.53gold quality
periodontal ligamentUBERON:000826659.50gold quality
secondary oocyteCL:000065559.39gold quality
oocyteCL:000002359.32gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-MTAB-9841yes553.93
E-MTAB-10855yes446.74
E-MTAB-7303no94.25
E-ANND-3no4.35

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPB, DDIT3

miRNA regulators (miRDB)

18 targeting CA6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-498-5P99.7669.641807
HSA-MIR-556-3P99.7468.751203
HSA-MIR-1252-3P99.5567.712862
HSA-MIR-155-5P99.3570.161509
HSA-MIR-6731-5P99.2867.422375
HSA-MIR-10399-5P99.1769.872610
HSA-MIR-6504-3P99.1769.312891
HSA-MIR-6871-5P98.9066.67671
HSA-MIR-29B-1-5P98.8668.351364
HSA-MIR-6731-3P98.6167.86749
HSA-MIR-6878-5P98.4967.912142
HSA-MIR-6509-3P98.3267.331343
HSA-MIR-6826-3P98.1966.321153
HSA-MIR-30C-1-3P97.8066.361499
HSA-MIR-30C-2-3P97.8066.451499
HSA-MIR-6788-5P97.8066.411532
HSA-MIR-6748-3P97.2065.66836
HSA-MIR-675-5P92.9760.9566

Literature-anchored findings (GeneRIF, showing 29)

  • The cloning, expression and purification of this isozyme are reported. (PMID:17499996)
  • analysis of allele & genotype distribution of 3 polymorphisms in CA6 gene; no association between polymorphisms in exons 2 & 3 & caries experience; positive association between salivary buffer capacity & rs2274327 (PMID:19721466)
  • The gustin gene dimorphism rs2274333 observed in supertaster and nontaster subjects may influence the protein conformation and, thereby, affect zinc ion binding. (PMID:20631203)
  • The polymerase chain reaction followed by restriction fragment length polymorphism assay described here can be used as an alternative to sequencing in bitter taster status research, and could be employed as a survey tool in nutrigenomic studies. (PMID:21631296)
  • The data of this study showed how the combination of the TAS2R38 and gustin gene genotypes modulate PROP phenotype. (PMID:21712049)
  • The aim of this study was to investigate carbonic anhydrase (CA) VI Exon 2 single nucleotide polymorphism (SNP) and its possible association with salivary parameters in type 2 diabetic patients compared to healthy adults. (PMID:22198626)
  • The 1.9A crystal structure of the human CA VI catalytic domain reveals a prototypical mammalian CA fold, and a novel dimeric arrangement as compared to previously-reported CA structures. (PMID:22366092)
  • results suggest that polymorphisms in the CA6 gene are associated with the concentrations of secreted CA VI. (PMID:23652931)
  • The rs2274333 polymorphism of the gustin gene affects PROP sensitivity. (PMID:24040192)
  • SNPs associated with taste perception and taste bud anatomy (PMID:24534176)
  • Study showed that PROP (6-n-propylthiouracil) bitterness was due to TAS2R38 diplotypes, whereas the density of fungiform papillae was more closely associated with gustin genotypes (PMID:25447475)
  • We also found that the haplotype (ACA) (rs2274328, rs17032907 and rs11576766)of the carbonic anhydrase VI was associated with a low number of decayed, missing, and filled teeth index with an odds ratio (95% confidence interval) of 0.635 (0.440-0.918). (PMID:26125798)
  • CA6 is a specific marker for serous acinar cells of salivary glands and acinic cell carcinoma (AciCC). (PMID:26212680)
  • dental plaque amount, lactobacilli count, age, and saliva buffer capacity, as well as CA6 (T55M) gene polymorphism, explained total of 87.8% of variations in DMFT scores. (PMID:26377569)
  • Results found that the CA VI gene polymorphism rs2274327 showed no correlation between salivary parameters and dental-oral health status in Eastern Anatolian Turkish children. (PMID:27100223)
  • genetic association studies in population of elderly women in Poland: Data suggest that SNPs in TAS2R38 (rs713598, rs1726866, rs10246939) and an SNP in CA6 (rs2274333) are associated with intake of and preferences for some foods (coffee and white cabbage) among the population studied. (TAS2R38 = taste receptor type 2 member 38; CA6 = carbonic anhydrase VI) (PMID:28455260)
  • The current study suggests that genetic variation in TAS2R38 and CA6 influences picky eating in preschoolers. (PMID:28858874)
  • Anti-CA6 was the most prevalent novel autoantibody in patients with dry eye, and was associated with younger age and more severe disease. Longitudinal studies are needed to determine whether anti-CA6 is a marker for early Sjogren’s syndrome. (PMID:29504954)
  • Results indicate that carbonic anhydrase VI (CA6) gene polymorphisms influence Streptococcus mutans colonization, tooth biofilm microbiota composition and risk of dental caries in Swedish adolescents. (PMID:30679524)
  • Polymorphism in the CAVI gene can affect salivary properties but there is no direct connection with dental caries. (PMID:32013665)
  • Taste Changes in Patients with Inflammatory Bowel Disease: Associations with PROP Phenotypes and polymorphisms in the salivary protein, Gustin and CD36 Receptor Genes. (PMID:32033224)
  • Investigation of carbonic anhydrase 6 gene polymorphism rs2274327 in relation to the oral health status and salivary composition in type 2 diabetic patients. (PMID:32319846)
  • Combined effect of starch and sucrose on carbonic anhydrase VI activity in saliva and biofilm of children with early childhood caries. Exposure to starch and sucrose alters carbonic anhydrase VI activity in saliva and biofilm. (PMID:32918121)
  • Associations of the activity and concentration of carbonic anhydrase VI with susceptibility to dental caries: A systematic review and meta-analysis. (PMID:36815304)
  • Association between Carbonic Anhydrase VI Gene Copy Number Variations and Dental Caries Experience. (PMID:37011600)
  • The gustin gene variation at rs2274333 and PROP taster status affect dietary fat perception: a stepwise multiple regression model study. (PMID:38467201)
  • Association of the bitter taste genes TAS2R38 and CA6 and breast cancer risk; a case-control study of Polish women in Poland and Polish immigrants in USA. (PMID:38687739)
  • Gene Methylation Affects Salivary Levels of the Taste Buds’ Trophic Factor, Gustin Protein. (PMID:38732551)
  • Association between LTF/MMP20/CA6/TAS1R2 polymorphisms and susceptibility to dental caries. (PMID:39212776)

Cross-species orthologs

17 orthologs

OrganismSymbolGene ID
danio_rerioca6ENSDARG00000056499
mus_musculusCar6ENSMUSG00000028972
rattus_norvegicusCar6ENSRNOG00000021355
drosophila_melanogasterCAH13FBGN0033542
drosophila_melanogasterCAH14FBGN0034554
drosophila_melanogasterCAH15FBGN0034560
drosophila_melanogasterCAH7FBGN0037788
drosophila_melanogasterCAH8FBGN0038956
drosophila_melanogasterCAH4FBGN0039235
drosophila_melanogasterCAH9FBGN0039486
drosophila_melanogasterCAH6FBGN0039838
drosophila_melanogasterCAH16FBGN0040628
drosophila_melanogasterCAH5FBGN0040629
drosophila_melanogasterCARPBFBGN0052698
caenorhabditis_elegansWBGENE00000279
caenorhabditis_elegansWBGENE00000283
caenorhabditis_eleganscah-6WBGENE00000284

Paralogs (14): CA11 (ENSG00000063180), CA12 (ENSG00000074410), CA2 (ENSG00000104267), CA9 (ENSG00000107159), CA14 (ENSG00000118298), CA1 (ENSG00000133742), CA10 (ENSG00000154975), CA3 (ENSG00000164879), CA4 (ENSG00000167434), CA7 (ENSG00000168748), CA5B (ENSG00000169239), CA5A (ENSG00000174990), CA8 (ENSG00000178538), CA13 (ENSG00000185015)

Protein

Protein identifiers

Carbonic anhydrase 6 — P23280 (reviewed: P23280)

Alternative names: Carbonate dehydratase VI, Carbonic anhydrase VI, Salivary carbonic anhydrase, Secreted carbonic anhydrase

All UniProt accessions (3): P23280, F8W148, Q8N4G4

UniProt curated annotations — full annotation on UniProt →

Function. Reversible hydration of carbon dioxide. Its role in saliva is unknown.

Subcellular location. Secreted.

Tissue specificity. Major constituent of saliva.

Activity regulation. Inhibited by coumarins, sulfonamide derivatives such as acetazolamide (AZA), saccharin and Foscarnet (phosphonoformate trisodium salt).

Similarity. Belongs to the alpha-carbonic anhydrase family.

Isoforms (3)

UniProt IDNamesCanonical?
P23280-11yes
P23280-22
P23280-33

RefSeq proteins (4): NP_001206, NP_001257429, NP_001257430, NP_001257431 (=MANE)

Domains & families (InterPro)

IDNameType
IPR001148CA_domDomain
IPR018338Carbonic_anhydrase_a-class_CSConserved_site
IPR023561Carbonic_anhydrase_a-classFamily
IPR036398CA_dom_sfHomologous_superfamily

Pfam: PF00194

Enzyme classification (BRENDA):

  • EC 4.2.1.1 — carbonic anhydrase (BRENDA: 178 organisms, 196 substrates, 2137 inhibitors, 263 Km, 291 kcat entries)

Substrate kinetics (BRENDA)

9 substrates with measured Km, best-characterized 9. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
CO20.012–4700194
4-NITROPHENYL ACETATE0.0024–30.5316
H2CO30.434–112.716
HCO3-9.3–374
P-NITROPHENYL ACETATE3.86–6.84
4-NITROPHENYL PHOSPHATE0.935–2.1952
COS1.861
HISTAMINE7.91
CS2—0

Catalyzed reactions (Rhea), 1 shown:

  • hydrogencarbonate + H(+) = CO2 + H2O (RHEA:10748)

UniProt features (46 total): strand 15, helix 9, sequence variant 6, binding site 4, sequence conflict 3, splice variant 2, glycosylation site 2, signal peptide 1, chain 1, disulfide bond 1, domain 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDBMethodResolution (Å)
3FE4X-RAY DIFFRACTION1.9

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-P23280-F189.490.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 85 (proton donor/acceptor)

Ligand- & substrate-binding residues (4): 111; 113; 138; 220–221

Disulfide bonds (1): 42–224

Glycosylation sites (2): 67, 256

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

IDPathway
R-HSA-1475029Reversible hydration of carbon dioxide
R-HSA-1430728Metabolism

MSigDB gene sets: 97 (showing top): GOMF_CARBONATE_DEHYDRATASE_ACTIVITY, GOBP_SENSORY_PERCEPTION_OF_CHEMICAL_STIMULUS, GOBP_DETECTION_OF_CHEMICAL_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION_OF_TASTE, MARTINEZ_RB1_TARGETS_DN, GOBP_SENSORY_PERCEPTION_OF_TASTE, MODULE_294, TGIF_01, MODULE_99, GOBP_DETECTION_OF_STIMULUS, GOBP_SENSORY_PERCEPTION, MARCINIAK_ER_STRESS_RESPONSE_VIA_CHOP, MODULE_295, GOMF_HYDRO_LYASE_ACTIVITY, XU_GH1_EXOGENOUS_TARGETS_DN, MODULE_343

GO Biological Process (1): detection of chemical stimulus involved in sensory perception of bitter taste (GO:0001580)

GO Molecular Function (5): carbonate dehydratase activity (GO:0004089), zinc ion binding (GO:0008270), protein binding (GO:0005515), lyase activity (GO:0016829), metal ion binding (GO:0046872)

GO Cellular Component (5): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

CategoryPathways
Metabolism1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
detection of chemical stimulus involved in sensory perception of taste1
sensory perception of bitter taste1
hydro-lyase activity1
transition metal ion binding1
binding1
catalytic activity1
cation binding1
cytoplasm1
extracellular vesicle1
intracellular anatomical structure1

Protein interactions and networks

STRING

1362 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
CA6CHST8Q9H2A9875
CA6SLC2A5P22732863
CA6CHST9Q7L1S5858
CA6CYP24A1Q07973806
CA6BPIFA2Q96DR5770
CA6ENO1P06733766
CA6CST4P01036681
CA6PIGRP01833679
CA6TAS2R38P59533664
CA6CHST10O43529660
CA6MUC7Q8TAX7656
CA6ALBP02768591
CA6SLC4A4Q9Y6R1578
CA6AZGP1P25311574
CA6NKX2-5P52952562

IntAct

11 interactions, top by confidence:

ABTypeScore
FRMD1A2ML1psi-mi:“MI:0914”(association)0.530
STK11A2ML1psi-mi:“MI:0914”(association)0.350
HBQ1IGLL5psi-mi:“MI:0914”(association)0.350
CA6PLXNA2psi-mi:“MI:0914”(association)0.350
CORO1CA2ML1psi-mi:“MI:0914”(association)0.350
TIMM10IGLL5psi-mi:“MI:0914”(association)0.350
CA6QSOX1psi-mi:“MI:0914”(association)0.350
C10orf53CST4psi-mi:“MI:0914”(association)0.350
RSRP1A2ML1psi-mi:“MI:0914”(association)0.350

BioGRID (70): KRT31 (Two-hybrid), KRT40 (Two-hybrid), NOTCH2NL (Two-hybrid), CA6 (Affinity Capture-MS), CA6 (Affinity Capture-MS), RHOBTB3 (Affinity Capture-MS), PLXNA3 (Affinity Capture-MS), NPC2 (Affinity Capture-MS), CA6 (Affinity Capture-MS), DDX19B (Affinity Capture-MS), CA6 (Affinity Capture-MS), IMMP1L (Affinity Capture-MS), CA6 (Affinity Capture-MS), PLXNA2 (Affinity Capture-MS), PTCD2 (Affinity Capture-MS)

ESM2 similar proteins: A0A7H0DN92, A0JN41, A7MAQ2, F4HUC4, F4IHR4, F4JIK2, O04846, O43570, O57211, P04195, P08060, P0DO50, P0DSY1, P0DSY2, P10731, P12890, P18761, P18915, P19021, P20508, P23280, P28651, P35219, P48284, P61215, P97467, Q10462, Q18932, Q20781, Q5PPN4, Q5R4U0, Q5TZ24, Q64444, Q68CI2, Q6RZI9, Q75N34, Q75N35, Q84UV8, Q865C0, Q866X6

Diamond homologs: A0ZSF2, A0ZSF3, A0ZSF4, A0ZSF5, A0ZSF6, A0ZSF7, B3A0P2, B3A0Q6, B8V7P3, F4HUC4, O43570, P08060, P18761, P22748, P23280, P23471, P23589, P35218, P43165, P48284, P83299, P84537, Q10462, Q16790, Q27504, Q27908, Q62656, Q84UV8, Q865C0, Q8CI85, Q8UWA5, Q8VHB5, Q92051, Q9ERQ8, Q9FM99, Q9MZ30, Q9NL38, Q9QZA0, Q9Y2D0, P07630

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic2
Likely pathogenic1
Uncertain significance52
Likely benign6
Benign2

Top pathogenic / likely-pathogenic (3)

Variant IDHGVSClassification
565070GRCh37/hg19 1p36.23-36.22(chr1:7331314-9427796)x1Pathogenic
565071GRCh37/hg19 1p36.23-36.22(chr1:7391956-9775929)x1Pathogenic
1807831GRCh37/hg19 1p36.23-36.22(chr1:8473813-9852687)x1Likely pathogenic

SpliceAI

1222 predictions. Top by Δscore:

VariantEffectΔscore
1:8949261:AGAAG:Aacceptor_gain1.0000
1:8949262:GAA:Gacceptor_gain1.0000
1:8949262:GAAGG:Gacceptor_gain1.0000
1:8958904:TTACA:Tacceptor_loss1.0000
1:8958905:TACA:Tacceptor_loss1.0000
1:8958906:ACAGA:Aacceptor_loss1.0000
1:8958907:CA:Cacceptor_loss1.0000
1:8958908:A:ACacceptor_loss1.0000
1:8958908:A:AGacceptor_gain1.0000
1:8958909:G:GGacceptor_gain1.0000
1:8958909:G:GTacceptor_loss1.0000
1:8959001:AGGT:Adonor_loss1.0000
1:8959002:GGTA:Gdonor_loss1.0000
1:8959003:G:GGdonor_gain1.0000
1:8959003:G:Tdonor_loss1.0000
1:8959004:T:Gdonor_loss1.0000
1:8962581:CTGCA:Cacceptor_loss1.0000
1:8962582:TGCA:Tacceptor_loss1.0000
1:8962583:GCAG:Gacceptor_loss1.0000
1:8962584:CA:Cacceptor_loss1.0000
1:8962585:A:AGacceptor_gain1.0000
1:8962585:AGG:Aacceptor_loss1.0000
1:8962586:G:GTacceptor_gain1.0000
1:8962586:GGT:Gacceptor_gain1.0000
1:8962655:AGG:Adonor_loss1.0000
1:8962656:GGTA:Gdonor_loss1.0000
1:8962657:G:GAdonor_loss1.0000
1:8962657:G:GGdonor_gain1.0000
1:8962658:T:Gdonor_loss1.0000
1:8967652:T:TAacceptor_gain1.0000

AlphaMissense

2028 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
1:8949288:G:CW35C0.998
1:8949288:G:TW35C0.998
1:8967759:C:GC224W0.997
1:8970927:C:AR264S0.997
1:8957214:C:GH113D0.996
1:8957219:G:CW114C0.996
1:8957219:G:TW114C0.996
1:8967758:G:AC224Y0.996
1:8949308:G:AC42Y0.995
1:8949309:T:GC42W0.995
1:8949329:C:AP49H0.995
1:8949429:C:AN82K0.995
1:8949429:C:GN82K0.995
1:8967737:G:TG217V0.995
1:8967757:T:AC224S0.995
1:8967757:T:CC224R0.995
1:8967758:G:CC224S0.995
1:8967775:T:AW230R0.995
1:8967775:T:CW230R0.995
1:8970953:A:CR272S0.995
1:8970953:A:TR272S0.995
1:8949286:T:AW35R0.994
1:8949286:T:CW35R0.994
1:8957217:T:AW114R0.994
1:8957217:T:CW114R0.994
1:8957251:A:TE125V0.994
1:8967739:T:CS218P0.994
1:8967743:T:CL219P0.994
1:8957252:G:CE125D0.993
1:8957252:G:TE125D0.993

dbSNP variants (sampled 300 via entrez): RS1000049368 (1:8973268 C>T), RS1000082108 (1:8956902 C>T), RS1000176600 (1:8972208 C>T), RS1000271047 (1:8963128 G>A), RS1000305566 (1:8951310 G>A), RS1000448919 (1:8969870 A>C), RS1000460832 (1:8961977 C>T), RS1000585051 (1:8956026 C>T), RS1000659538 (1:8974787 A>G,T), RS1000702559 (1:8945590 C>T), RS1000708157 (1:8962827 T>C), RS1000777549 (1:8974944 T>C), RS1001296897 (1:8956597 C>T), RS1001328638 (1:8947350 C>T), RS1001369006 (1:8947987 G>A)

Disease associations

OMIM: gene MIM:114780 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

StudyTraitp-value
GCST003262_875Post bronchodilator FEV14.000000e-06
GCST006585_1479Blood protein levels2.000000e-106
GCST006585_30Blood protein levels9.000000e-113

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0004314forced expiratory volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2095180 (PROTEIN FAMILY), CHEMBL3025 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

47 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 788,151 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL19METHAZOLAMIDE465
CHEMBL20ACETAZOLAMIDE428,768
CHEMBL750ZONISAMIDE416,649
CHEMBL1054TRICHLORMETHIAZIDE411,619
CHEMBL1055CHLORTHALIDONE420,442
CHEMBL118CELECOXIB4112,844
CHEMBL1200471PYRITHIONE ZINC424,834
CHEMBL1286LEVETIRACETAM413,997
CHEMBL17DICHLORPHENAMIDE49,022
CHEMBL18ETHOXZOLAMIDE43,042
CHEMBL21SULFANILAMIDE4153,075
CHEMBL2105581VERALIPRIDE41,165
CHEMBL218490DORZOLAMIDE410,216
CHEMBL220491BRINZOLAMIDE48,355
CHEMBL220492TOPIRAMATE435,160
CHEMBL255863NILOTINIB438,627
CHEMBL26SULPIRIDE458,543
CHEMBL325041BORTEZOMIB413,120
CHEMBL328560SULTHIAME44,563
CHEMBL35FUROSEMIDE4224,045
CHEMBL406INDAPAMIDE4
CHEMBL419MAFENIDE4
CHEMBL424SALICYLIC ACID4
CHEMBL506247TANNIC ACID4
CHEMBL58323LACOSAMIDE4
CHEMBL609TRIENTINE4
CHEMBL6466COUMARIN4
CHEMBL865VALDECOXIB4
CHEMBL902FAMOTIDINE4
CHEMBL926DOBUTAMINE4

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

71 measured of 109 human assays (156 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValue
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acidEC500.0469 nM
aliphatic sulfamate, 1KI3.7 nM
2-(hydrazinecarbonyl)-3-(2-methylphenyl)-1H-indole-5-sulfonamideKI107 nM
3-(2-bromophenyl)-2-(hydrazinecarbonyl)-1H-indole-5-sulfonamideKI110 nM
Topiramate, 3KI250 nM
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamateIC50300 nM
JFD00715KI328 nM
trichloromethiazide, 6KI345 nM
bis-sulfamate, 3KI378 nM
N-(p-sulfamoylphenyl)-alpha-glycopyranosylamine, 7KI510 nM
aliphatic sulfamate, 2KI530 nM
3-(2-fluorophenyl)-2-(hydrazinecarbonyl)-1H-indole-5-sulfonamideKI621 nM
N-(p-sulfamoylphenyl)-alpha-glycopyranosylamine, 6KI630 nM
Investigational agent, 5KI810 nM
Investigational agent, 4KI850 nM
bis-sulfamate, 4KI890 nM
N-(p-sulfamoylphenyl)-alpha-glycopyranosylamine, 2KI1000 nM
4-Methyl-N-(4-nitrophenyl) benzenesulfonamide (11)IC501130 nM
N-(4-cyanophenyl)-4-methylbenzenesulfonamide (10)IC501480 nM
1,3,4-Thiadiazole-2-sulfonamide, 6IC502700 nM
BMCL182567 Compound 6bKI2840 nM
[2-(cycloheptylmethyl)-1,1-dioxo–benzothiophen-6-yl] sulfamateKI3600 nM
4-Methyl-N-(2-nitrophenyl) benzenesulfonamide (7)IC505380 nM
Carbonic anhydrase inhibitors (CAIs), 5KI5480 nM
Carbonic anhydrase inhibitors (CAIs), 6KI9340 nM
salicylic acidKI9900 nM
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamideKD10000 nM
phenolKI10200 nM
hCA inhibitor, 1KI13700 nM
Bis(3,4-dihydroxyphenyl)methanoneKI18000 nM
N-(2-cyanophenyl)-4-methylbenzenesulfonamide (6)IC5018200 nM
hCA inhibitor, 5KI18400 nM
Carbonic anhydrase inhibitors (CAIs), 7KI21700 nM
4-methylbenzene-1-sulfonamideIC5022100 nM
hCA inhibitor, 5KI24300 nM
hCA inhibitor, 6KI25300 nM
2-sulfanilamidopyrimidineIC5026200 nM
4-Amino-N-(pyrimidin-2-yl) benzenesulfonamide (Sulfadiazine) (14)IC5028400 nM
TETRABROMOCATECHOLKI32100 nM
9(R(S))-Hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-2(R(S))-yl sulfate (8)KI32700 nM
hCA inhibitor, 2KI37200 nM
3,5-difluorophenolKI38800 nM
trans-(1R(S),6R(S))-6-Hydroxycyclohex-3-enyl hydrogen sulfate (4)KI41300 nM
Brinzolamide, BRZKI45000 nM
hCA inhibitor, 3KI48100 nM
Dorzolamide, DZAKI50000 nM
Carbonic anhydrase inhibitors (CAIs), 1IC5050000 nM
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamideKI54000 nM
Carbonic anhydrase inhibitors (CAIs), 3KI70200 nM
hCA inhibitor, 4KI71200 nM

ChEMBL bioactivities

720 potent at pChembl≥5 of 792 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
10.17Kd0.067nMCHEMBL4441730
10.14Kd0.073nMCHEMBL4573916
10.05Ki0.09nMSULFAMATE
10.04Kd0.092nMCHEMBL4555622
10.00Kd0.1nMCHEMBL4475315
9.92Kd0.12nMCHEMBL4474251
9.85Kd0.14nMCHEMBL4517728
9.82Kd0.15nMCHEMBL4560953
9.80Kd0.16nMCHEMBL4463683
9.77Kd0.17nMCHEMBL4462447
9.77Kd0.17nMCHEMBL4562296
9.72Kd0.19nMCHEMBL4176862
9.70Kd0.2nMCHEMBL4165570
9.70Kd0.2nMCHEMBL4442511
9.70Ki0.2nMCHEMBL4552380
9.70Ki0.2nMCHEMBL4460315
9.70Ki0.2nMCHEMBL4434661
9.70Ki0.2nMCHEMBL282157
9.68Kd0.21nMCHEMBL4587295
9.68Kd0.21nMCHEMBL4558235
9.62Kd0.24nMCHEMBL4160149
9.60Kd0.25nMCHEMBL4464359
9.59Kd0.26nMCHEMBL4516072
9.57Kd0.27nMCHEMBL4160149
9.57Kd0.27nMCHEMBL4443078
9.57Kd0.27nMCHEMBL4553790
9.52Kd0.3nMCHEMBL4574321
9.52Kd0.3nMCHEMBL4466140
9.52Ki0.3nMP-CHLOROBENZENESULFONAMIDE
9.49Kd0.32nMCHEMBL4166643
9.49Kd0.32nMCHEMBL4444201
9.48Kd0.33nMCHEMBL4166643
9.46Kd0.35nMCHEMBL4539340
9.43Kd0.37nMCHEMBL4439909
9.43Kd0.37nMCHEMBL4474833
9.42Kd0.38nMCHEMBL4168966
9.42Kd0.38nMCHEMBL4516858
9.42Kd0.38nMCHEMBL4461481
9.42Kd0.38nMCHEMBL4457904
9.41Kd0.39nMCHEMBL4446249
9.40Kd0.4nMCHEMBL4170371
9.39Kd0.41nMCHEMBL4567916
9.37Kd0.43nMCHEMBL4449149
9.36Kd0.44nMCHEMBL4436290
9.36Kd0.44nMCHEMBL4517317
9.35Kd0.45nMCHEMBL4451500
9.28Kd0.53nMCHEMBL4573963
9.27Kd0.54nMCHEMBL4473602
9.27Kd0.54nMCHEMBL4458989
9.24Kd0.57nMCHEMBL4593434

PubChem BioAssay actives

844 with measured affinity, of 1307 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
1-(4-chlorosulfonyl-3,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic acid1763398: Inhibition of human recombinant CA6 assessed as intrinsic dissociation constant by thermal shift assaykd<0.0001uM
methyl 5-oxo-1-(4-sulfamoylphenyl)pyrrolidine-3-carboxylate1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd<0.0001uM
1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-N-[(E)-(4-methoxyphenyl)methylideneamino]-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
N-[(E)-benzylideneamino]-5-oxo-1-(4-sulfamoylphenyl)pyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
N-[(E)-(4-bromophenyl)methylideneamino]-1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
4-(2-chloro-3,5-dimethyl-4-sulfamoylanilino)-3-(4-phenyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)butanoic acid1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-N-[(E)-(4-nitrophenyl)methylideneamino]-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
1-(3,5-dimethyl-4-sulfamoylphenyl)-N-[(E)-(4-nitrophenyl)methylideneamino]-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-N-[(E)-(4-chlorophenyl)methylideneamino]-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0001uM
sulfamic acid552129: Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assayki0.0001uM
sulfamide552129: Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assayki0.0001uM
N-benzyl-2,4-dichloro-5-sulfamoylbenzamide1361387: Binding affinity to recombinant N-terminal His6-tagged human carbonic anhydrase 6 (21 to 290 residues) expressed in Escherichia coli Rosetta 2 (DE3) strain assessed as intrinsic Kd in presence of ANS by fluorescent thermal shift assaykd0.0002uM
N-benzyl-2-(benzylamino)-4-chloro-5-sulfamoylbenzamide1361387: Binding affinity to recombinant N-terminal His6-tagged human carbonic anhydrase 6 (21 to 290 residues) expressed in Escherichia coli Rosetta 2 (DE3) strain assessed as intrinsic Kd in presence of ANS by fluorescent thermal shift assaykd0.0002uM
N-benzyl-4-chloro-2-phenylsulfanyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0002uM
N-benzyl-4-chloro-2-cyclohexylsulfanyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0002uM
4-[1-[(2R)-1-(3-azabicyclo[3.2.2]nonan-3-yl)-3-methyl-1-oxobutan-2-yl]triazol-4-yl]benzenesulfonamide1557414: Inhibition of carbonic anhydrase (unknown origin)ki0.0002uM
1-(3-bromophenyl)-5-oxo-N-(4-sulfamoylphenyl)pyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0002uM
N-[(E)-benzylideneamino]-1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0002uM
(2R)-3-phenyl-2-[4-(4-sulfamoylphenyl)triazol-1-yl]-N-(2-thiophen-3-ylethyl)propanamide1557414: Inhibition of carbonic anhydrase (unknown origin)ki0.0002uM
1-(3,5-dimethyl-4-sulfamoylphenyl)-N-[(E)-(4-methoxyphenyl)methylideneamino]-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0002uM
N-[(E)-(4-chlorophenyl)methylideneamino]-1-(3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0002uM
4-nitrobenzenesulfonamide50173: Compound was evaluated for the inhibition of Carbonic anhydraseki0.0002uM
N-butyl-2,4-dichloro-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0002uM
(2R)-N-benzyl-3-methyl-2-[4-(4-sulfamoylphenyl)triazol-1-yl]butanamide1557414: Inhibition of carbonic anhydrase (unknown origin)ki0.0002uM
2-benzylsulfanyl-N-butyl-4-chloro-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0003uM
N-butyl-4-chloro-2-phenylsulfanyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0003uM
N-butyl-4-chloro-2-(2-phenylethylsulfanyl)-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0003uM
2,4-dibromo-N-butyl-5-sulfamoylbenzamide1361387: Binding affinity to recombinant N-terminal His6-tagged human carbonic anhydrase 6 (21 to 290 residues) expressed in Escherichia coli Rosetta 2 (DE3) strain assessed as intrinsic Kd in presence of ANS by fluorescent thermal shift assaykd0.0003uM
N-[(E)-(4-bromophenyl)methylideneamino]-1-(3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0003uM
1-[[1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carbonyl]amino]-3-phenylthiourea1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0003uM
3-chloro-2,6-dimethyl-4-[2-oxo-4-(4-phenyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)pyrrolidin-1-yl]benzenesulfonamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0003uM
1-(2-bromophenyl)-5-oxo-N-(4-sulfamoylphenyl)pyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0003uM
5-oxo-1-phenyl-N-(4-sulfamoylphenyl)pyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0003uM
4-chlorobenzenesulfonamide50173: Compound was evaluated for the inhibition of Carbonic anhydraseki0.0003uM
2-benzylsulfanyl-4-bromo-N-butyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0004uM
2-(benzenesulfonyl)-N-benzyl-4-chloro-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0004uM
2-(benzylamino)-4-chloro-N-(2-methoxyethyl)-5-sulfamoylbenzamide1361387: Binding affinity to recombinant N-terminal His6-tagged human carbonic anhydrase 6 (21 to 290 residues) expressed in Escherichia coli Rosetta 2 (DE3) strain assessed as intrinsic Kd in presence of ANS by fluorescent thermal shift assaykd0.0004uM
2-(benzylamino)-4-chloro-N-(2-hydroxyethyl)-5-sulfamoylbenzamide1361387: Binding affinity to recombinant N-terminal His6-tagged human carbonic anhydrase 6 (21 to 290 residues) expressed in Escherichia coli Rosetta 2 (DE3) strain assessed as intrinsic Kd in presence of ANS by fluorescent thermal shift assaykd0.0004uM
N-butyl-4-chloro-2-cyclohexylsulfanyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0004uM
1-(3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxylic acid1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
N-(3,5-dimethylpyrazol-1-yl)-1-(3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
3-chloro-2,6-dimethyl-4-[2-oxo-4-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)pyrrolidin-1-yl]benzenesulfonamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-N-(3,5-dimethylpyrazol-1-yl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
N-[(E)-benzylideneamino]-1-(3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
3-chloro-4-[4-(3,5-dimethylpyrazole-1-carbonyl)-2-oxopyrrolidin-1-yl]-2,6-dimethylbenzenesulfonamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
4-[4-(3,5-dimethylpyrazole-1-carbonyl)-2-oxopyrrolidin-1-yl]-2,6-dimethylbenzenesulfonamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
5-oxo-1-(4-sulfamoylphenyl)pyrrolidine-3-carboxylic acid1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0004uM
N-benzyl-4-chloro-2-cyclohexylsulfonyl-5-sulfamoylbenzamide1520085: Binding affinity to recombinant human carbonic anhydrase 6 expressed in Escherichia coli expression system assessed as kinetic dissociation constant fluorescent thermal shift assaykd0.0005uM
3-chloro-4-[4-(hydrazinecarbonyl)-2-oxopyrrolidin-1-yl]-2,6-dimethylbenzenesulfonamide1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0005uM
methyl 1-(2-chloro-3,5-dimethyl-4-sulfamoylphenyl)-5-oxopyrrolidine-3-carboxylate1515320: Binding affinity to recombinant human CA6 assessed as intrinsic dissociation constant by DSF-based fluorescence thermal shift assaykd0.0005uM

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

ChemicalActions (top 5)PubMed papers
oryzalinaffects binding, decreases activity1
perfluorooctanoic acidincreases expression1
1-nitropyrenedecreases expression1
perfluorooctane sulfonic acidincreases expression1
2-palmitoylglycerolincreases expression1
perfluorohexanesulfonic acidincreases expression1
(+)-JQ1 compounddecreases expression1
Acetazolamideaffects binding, decreases activity1
Arsenicaffects expression1
Carmustinedecreases expression1
Nickeldecreases expression1
Propylthiouracilaffects response to substance1
Tretinoinincreases expression1
Famotidineaffects binding, decreases activity1
Aflatoxin B1increases methylation1

ChEMBL screening assays

107 unique, capped per target: 105 binding, 2 admet

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL3386760BindingInhibition of carbonic anhydrase (unknown origin)Substituted thieno[2,3-b]thiophenes and related congeners: Synthesis, β-glucuronidase inhibition activity, crystal structure, and POM analyses. — Bioorg Med Chem
CHEMBL4187337ADMETBinding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 6 expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assayBenzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 79

This page pulls from 79 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot